Evidence map›Paper›PMID 27379837›Full record

ArticleJournal of neurochemistry2016

Traumatic brain injury decreases AMP-activated protein kinase activity and pharmacological enhancement of its activity improves cognitive outcome.

Julia L Hill, Nobuhide Kobori, Jing Zhao, Natalia S Rozas, Michael J Hylin, Anthony N Moore, Pramod K Dash

Open access · greenAbstract read
In one paragraph

Article in Journal of neurochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Mitochondrial-targeted therapies in traumatic brain injury: From bench to bedside.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. The Cerebral Protective Effect of Novel Erinacines fromAntioxidants (Basel, Switzerland) · 2024
    Article
  18. Article
  19. Neuroprotective effects of hesperetin on HNutrition research and practice · 2023
    Article
  20. CRTC1 is a potential target to delay aging-induced cognitive deficit by protecting the integrity of the blood-brain barrier via inhibiting inflammation.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julia L HillDepartment of Neurobiology and Anatomy, McGovern Medical School, Houston, Texas, USA.
Nobuhide KoboriDepartment of Neurobiology and Anatomy, McGovern Medical School, Houston, Texas, USA.
Jing ZhaoDepartment of Neurobiology and Anatomy, McGovern Medical School, Houston, Texas, USA.
Natalia S RozasDepartment of Neurobiology and Anatomy, McGovern Medical School, Houston, Texas, USA.
Michael J HylinDepartment of Neurobiology and Anatomy, McGovern Medical School, Houston, Texas, USA.
Anthony N MooreDepartment of Neurobiology and Anatomy, McGovern Medical School, Houston, Texas, USA.
Pramod K DashDepartment of Neurobiology and Anatomy, McGovern Medical School, Houston, Texas, USA. p.dash@uth.tmc.edu.

Funding

Reducing Neuronal Loss After Traumatic Brain InjuryR01NS090935 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DASH, PRAMOD K · 2015 to 2019
$2.1M
The role of mitochondrial fission in TBI outcomeR01NS101686 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DASH, PRAMOD K, WAXHAM, M. NEAL · 2017 to 2021
$2.1M
Role of Glut4 in TBI PathophysiologyR01NS086301 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DASH, PRAMOD K · 2015 to 2019
$1.7M
NINDS NIH HHS R01 NS086301NINDS NIH HHS R01 NS090935NINDS NIH HHS R01 NS101686
6 · The paper itself

Abstract

Prolonged metabolic suppression in the brain is a well-characterized secondary pathology of both experimental and clinical traumatic brain injury (TBI). AMP-activated kinase (AMPK) acts as a cellular energy sensor that, when activated, regulates various metabolic and catabolic pathways to decrease ATP consumption and increase ATP synthesis. As energy availability after TBI is suppressed, we questioned if increasing AMPK activity after TBI would improve cognitive outcome. TBI was delivered using the electromagnetic controlled cortical impact model on male Sprague-Dawley rats (275-300 g) and C57BL/6 mice (20-25 g). AMPK activity within the injured parietal cortex and ipsilateral hippocampus was inferred by western blots using phospho-specific antibodies. The consequences of acute manipulation of AMPK signaling on cognitive function were assessed using the Morris water maze task. We found that AMPK activity is decreased as a result of injury, as indicated by reduced AMPK phosphorylation and corresponding changes in the phosphorylation of its downstream targets: ribosomal protein S6 and Akt Substrate of 160 kDa (AS160). Increasing AMPK activity after injury using the drugs 5-amino-1-β-d-ribofuranosyl-imidazole-4-carboxamide or metformin did not affect spatial learning, but significantly improved spatial memory. Taken together, our results suggest that decreased AMPK activity after TBI may contribute to the cellular energy crisis in the injured brain, and that AMPK activators may have therapeutic utility. Increased phosphorylation of Thr172 activates AMP-activated protein kinase (AMPK) under conditions of low cellular energy availability. This leads to inhibition of energy consuming, while activating energy generating, processes. Hill et al., present data to indicate that TBI decreases Thr172 phosphorylation and that its stimulation by pharmacological agents offers neuroprotection and improves memory. These results suggest that decreased AMPK phosphorylation after TBI incorrectly signals the injured brain that excess energy is available, thereby contributing to the cellular energy crisis and memory impairments.

Indexed as

Aminoimidazole CarboxamideAMP-Activated Protein KinasesAnimalsBrain Injuries, TraumaticEnzyme ActivatorsHippocampusMaleMaze LearningMemory DisordersMetforminMiceMice, Inbred C57BLNeuroprotective AgentsNootropic AgentsParietal LobePhosphorylationAICA ribonucleotideAminoimidazole CarboxamideAMP-Activated Protein KinasesEnzyme ActivatorsMetforminNeuroprotective AgentsNootropic AgentsRibonucleotidesglucose metabolismhippocampusmemory retentiontraumatic brain injury

Identifiers

PMID27379837
PMCPMC5037010
OpenAlexW2461388993

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.